A new anti-tumor cytotoxic triterpene from Ganoderma lucidum. Issue 16 (29th July 2022)

• Record Type: Journal Article
• Authors: Cao, Liping; Jin, Hongliu; Liang, Qi; Yang, Haiyi; Li, Shuguang; Liu, Zhicheng; Yuan, Zhongwen
• Is Part Of: Natural product research. Volume 36:Issue 16(2022)
• Page Start: 4125
• Page End: 4131
• Publication Date: 2022-07-29
• Subjects: Ganoderma lucidum -- anti-cancer -- HepG2 -- A549 -- p53 -- apoptosis; Natural products -- Periodicals; Natural products -- Research -- Periodicals; Biological Factors -- Periodicals; Biological Products -- Periodicals; 547
• DOI: 10.1080/14786419.2021.1976175
• Languages: English
• ISSNs: 1478-6419

Abstract

Abstract: Ganoderma lucidum ( G. lucidum ) is a famous medicinal fungus used as a traditional medicine for generations in China. Among bioactivities that G. lucidum possesses, the anti-tumor effect has aroused extensive interests. In this study, one new triterpene (1 ) was isolated from 90% ethanol extract of the dried fruiting bodies of G. lucidum . Its structure was determined based on the analysis of its spectroscopic data, including 1 D and 2 D NMR and MS spectra. Furthermore, 1 elicited moderate anti-tumor activities (IC50 values of 15.38 ± 0.34 and 18.61 ± 0.55 μM for A549 and HepG2 cells, respectively) compared with cisplatin which was employed as the positive drug with IC50 values of 8.21 ± 0.17 and 5.36 ± 0.29 μM for A549 and HepG2 cells, respectively. The mechanism study by RT-qPCR and western blot analysis suggested that the p53/caspase-3 pathway is involved in the 1 -induced apoptosis. Graphical Abstract: UF0001